Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium

Completed · Phase 1

Conditions studied: Bladder Cancer, Urethral Cancer

In brief

RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of urothelial cancer. PURPOSE: This randomized phase I trial is studying how well low-dose interferon alfa works in treating patients with cancer of the urothelium.

Key facts

Study ID

NCT00082719

Run by

M.D. Anderson Cancer Center

People needed

33

Starts

2003-12-01

Expected to finish

2015-01-01

Last updated by the study team

2015-05-14

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have histologically proven urothelial cancer, known or suspected (e.g. by outside evaluation) to be muscle-invasive, and be scheduled for cystoscopy and transurethral biopsy as part of their routine evaluation at M. D. Anderson.
• Patients must understand the investigational nature of this study and provide written, informed consent.

You may not qualify if…

• Patients who are pregnant or lactating are not eligible. Women of child-bearing potential must have a negative pregnancy test before starting therapy.
• Patients with current symptoms suggestive of clinically significant affective disorder.
• Patients taking more than physiologic replacement doses of corticosteroids are not eligible.

Where it is running

• University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.